Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease
Objective This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). Methods Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, includ...
Saved in:
Published in | Annals of neurology Vol. 89; no. 1; pp. 165 - 176 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.01.2021
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective
This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD).
Methods
Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K‐SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell–inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs.
Results
GCIPL thickness in the parafoveal region (1‐ to 3‐mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10–11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03–10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration.
Interpretation
Our results provide evidence of the potential use of optical coherence tomography–measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165–176 |
---|---|
AbstractList | ObjectiveThis study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD).MethodsPatients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K‐SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell–inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs.ResultsGCIPL thickness in the parafoveal region (1‐ to 3‐mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10–11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03–10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration.InterpretationOur results provide evidence of the potential use of optical coherence tomography–measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165–176 This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K-SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell-inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs. GCIPL thickness in the parafoveal region (1- to 3-mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10-11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03-10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. Our results provide evidence of the potential use of optical coherence tomography-measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165-176. Objective This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). Methods Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K‐SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell–inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs. Results GCIPL thickness in the parafoveal region (1‐ to 3‐mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10–11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03–10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. Interpretation Our results provide evidence of the potential use of optical coherence tomography–measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165–176 Objective This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). Methods Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K‐ SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell–inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs. Results GCIPL thickness in the parafoveal region (1‐ to 3‐mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls ( p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10–11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03–10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. Interpretation Our results provide evidence of the potential use of optical coherence tomography–measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165–176 OBJECTIVEThis study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). METHODSPatients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K-SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell-inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs. RESULTSGCIPL thickness in the parafoveal region (1- to 3-mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10-11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03-10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. INTERPRETATIONOur results provide evidence of the potential use of optical coherence tomography-measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165-176. |
Author | Cortes, Jesus Ayala, Unai Galdós, Marta Gabilondo, Iñigo Fernández‐Valle, Tamara Tijero, Beatriz Arana, Begoña Barrenechea, Maitane Murueta‐Goyena, Ane Carmona‐Abellán, Mar Del Pino, Rocío Peña, Javier Lucas‐Jiménez, Olaia Gómez‐Esteban, Juan Carlos Ojeda, Natalia Ibarretxe‐Bilbao, Naroa Acera, Marian |
AuthorAffiliation | 8 Computational Neuroimaging Group Biocruces Bizkaia Health Research Institute Barakaldo Spain 5 Neurology Department Cruces University Hospital Barakaldo Spain 9 Ikerbasque: The Basque Foundation for Science Bilbao Spain 10 Biomedical Engineering Department, Faculty of Engineering Mondragon University Mondragon Spain 4 Ophthalmology Department Cruces University Hospital Barakaldo Spain 3 International University of La Rioja Logroño Spain 1 Neurodegenerative Diseases Group Biocruces Bizkaia Health Research Institute Barakaldo Spain 2 Department of Physiology University of the Basque Country (Universidad del País Vasco / Euskal Herriko Unibertsitatea) Leioa Spain 6 Department of Neurosciences University of the Basque Country (UPV/EHU) Leioa Spain 7 Department of Methods and Experimental Psychology, Faculty of Psychology and Education University of Deusto Bilbao Spain |
AuthorAffiliation_xml | – name: 2 Department of Physiology University of the Basque Country (Universidad del País Vasco / Euskal Herriko Unibertsitatea) Leioa Spain – name: 9 Ikerbasque: The Basque Foundation for Science Bilbao Spain – name: 3 International University of La Rioja Logroño Spain – name: 6 Department of Neurosciences University of the Basque Country (UPV/EHU) Leioa Spain – name: 8 Computational Neuroimaging Group Biocruces Bizkaia Health Research Institute Barakaldo Spain – name: 10 Biomedical Engineering Department, Faculty of Engineering Mondragon University Mondragon Spain – name: 4 Ophthalmology Department Cruces University Hospital Barakaldo Spain – name: 1 Neurodegenerative Diseases Group Biocruces Bizkaia Health Research Institute Barakaldo Spain – name: 5 Neurology Department Cruces University Hospital Barakaldo Spain – name: 7 Department of Methods and Experimental Psychology, Faculty of Psychology and Education University of Deusto Bilbao Spain |
Author_xml | – sequence: 1 givenname: Ane orcidid: 0000-0002-9808-6943 surname: Murueta‐Goyena fullname: Murueta‐Goyena, Ane email: ane.muruetagoyena@osakidetza.eus organization: University of the Basque Country (Universidad del País Vasco / Euskal Herriko Unibertsitatea) – sequence: 2 givenname: Rocío surname: Del Pino fullname: Del Pino, Rocío organization: International University of La Rioja – sequence: 3 givenname: Marta surname: Galdós fullname: Galdós, Marta organization: Cruces University Hospital – sequence: 4 givenname: Begoña surname: Arana fullname: Arana, Begoña organization: Cruces University Hospital – sequence: 5 givenname: Marian surname: Acera fullname: Acera, Marian organization: Biocruces Bizkaia Health Research Institute – sequence: 6 givenname: Mar orcidid: 0000-0002-3765-1005 surname: Carmona‐Abellán fullname: Carmona‐Abellán, Mar organization: Biocruces Bizkaia Health Research Institute – sequence: 7 givenname: Tamara surname: Fernández‐Valle fullname: Fernández‐Valle, Tamara organization: University of the Basque Country (UPV/EHU) – sequence: 8 givenname: Beatriz surname: Tijero fullname: Tijero, Beatriz organization: Cruces University Hospital – sequence: 9 givenname: Olaia orcidid: 0000-0002-7715-3764 surname: Lucas‐Jiménez fullname: Lucas‐Jiménez, Olaia organization: University of Deusto – sequence: 10 givenname: Natalia surname: Ojeda fullname: Ojeda, Natalia organization: University of Deusto – sequence: 11 givenname: Naroa surname: Ibarretxe‐Bilbao fullname: Ibarretxe‐Bilbao, Naroa organization: University of Deusto – sequence: 12 givenname: Javier surname: Peña fullname: Peña, Javier organization: University of Deusto – sequence: 13 givenname: Jesus surname: Cortes fullname: Cortes, Jesus organization: Ikerbasque: The Basque Foundation for Science – sequence: 14 givenname: Unai surname: Ayala fullname: Ayala, Unai organization: Mondragon University – sequence: 15 givenname: Maitane surname: Barrenechea fullname: Barrenechea, Maitane organization: Mondragon University – sequence: 16 givenname: Juan Carlos surname: Gómez‐Esteban fullname: Gómez‐Esteban, Juan Carlos organization: University of the Basque Country (UPV/EHU) – sequence: 17 givenname: Iñigo orcidid: 0000-0001-6045-2840 surname: Gabilondo fullname: Gabilondo, Iñigo organization: Ikerbasque: The Basque Foundation for Science |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33098308$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU1PGzEURa0K1ATaRf8AssSmXQz4c5zZIEWhUCTaRhFdWx7Pc2IysYM9oeLfMyEUUSRWb_GOjq7uPUB7IQZA6AslJ5QQdmqCOWGyEuIDGlLJaTFiotpDQ8JLUUjKxQAd5HxLCKlKSj6iAeekGnEyGqKfM-h8MC2-WXi7DJAzniZovO0y7haAZz4vcXR4EufBd_4e8DnY1gfAPuCpSUsfcgz43GcwGT6hfWfaDJ-f7yH6c_H9ZvKjuP59eTUZXxdWCC4KxUjNja2ZNGVtKxBM9ekZVXXdVMZJVwolHVEMStsQ4ShTjapq52wNhFvGD9HZzrve1CtoLIQumVavk1-Z9KCj8fr_T_ALPY_3WilZlqLsBV-fBSnebSB3euWzhbY1AeImayakoH1xI9Wjx2_Q27hJfWVbShFRccm21LcdZVPMOYF7CUOJ3o6k-5H000g9e_Q6_Qv5b5UeON0Bf30LD--b9PjXeKd8BDFhnU4 |
CitedBy_id | crossref_primary_10_1038_s41467_024_49949_9 crossref_primary_10_1016_j_ajpath_2024_01_017 crossref_primary_10_1016_j_ebiom_2023_104615 crossref_primary_10_1016_j_neurobiolaging_2023_01_015 crossref_primary_10_1016_j_parkreldis_2024_107037 crossref_primary_10_3390_biom13020218 crossref_primary_10_3233_JPD_212775 crossref_primary_10_1038_s41531_024_00637_x crossref_primary_10_3390_biomedicines11020573 crossref_primary_10_3233_JPD_223481 crossref_primary_10_1093_brain_awac317 crossref_primary_10_1016_j_ajo_2023_10_005 crossref_primary_10_1097_MD_0000000000035354 crossref_primary_10_1111_jnp_12307 crossref_primary_10_1007_s00415_021_10703_6 crossref_primary_10_1016_j_euroneuro_2021_10_374 crossref_primary_10_1016_j_parkreldis_2024_106063 crossref_primary_10_1186_s41983_023_00701_y crossref_primary_10_3390_jimaging8050139 crossref_primary_10_1016_j_jns_2021_120015 crossref_primary_10_3390_proteomes10010004 crossref_primary_10_1016_j_nbd_2023_106379 crossref_primary_10_3390_jcm11092624 crossref_primary_10_1186_s40478_024_01782_3 crossref_primary_10_17116_jnevro20221221125 crossref_primary_10_1016_j_parkreldis_2021_10_005 crossref_primary_10_1002_mds_28602 crossref_primary_10_1136_bmjophth_2022_001061 crossref_primary_10_3389_fnins_2021_708700 crossref_primary_10_1136_jnnp_2022_329342 crossref_primary_10_1007_s00415_023_11720_3 crossref_primary_10_1007_s11065_022_09551_6 crossref_primary_10_1038_s41531_023_00611_z crossref_primary_10_1007_s11055_023_01487_5 crossref_primary_10_1007_s11910_024_01349_8 crossref_primary_10_1038_s41433_023_02438_7 crossref_primary_10_3389_fnins_2022_928980 crossref_primary_10_1038_s41582_022_00618_9 crossref_primary_10_1136_jnnp_2023_331083 crossref_primary_10_1002_cne_25481 crossref_primary_10_1016_j_wneu_2023_06_048 |
Cites_doi | 10.1002/ana.25696 10.1002/mds.27392 10.1002/mds.27728 10.1212/WNL.41.8.1200 10.1016/j.parkreldis.2019.04.023 10.3233/JPD-171184 10.1111/j.1532-5415.2005.53221.x 10.1371/journal.pone.0034823 10.2741/1171 10.1007/s10654-018-00478-y 10.1097/IAE.0000000000002641 10.1093/brain/aww175 10.1037/a0012949 10.3233/JPD-140470 10.1093/brain/110.6.1675 10.1001/archneur.59.8.1249 10.1167/iovs.16-20025 10.1002/ana.10795 10.1016/j.ophtha.2013.07.021 10.1093/brain/awt360 10.1212/CPJ.0000000000000719 10.1136/jnnp.47.7.673 10.1016/S1388-2457(99)00223-0 10.1212/WNL.40.11.1710 10.1001/archneurol.2009.295 10.1212/WNL.0000000000006157 10.1016/j.jns.2011.07.047 10.1212/WNL.0000000000000842 10.1167/iovs.16-20460 10.18637/jss.v067.i01 10.1167/iovs.17-23230 10.1111/aos.14291 10.1001/archneur.1984.04050170031011 10.1093/brain/awm111 10.1038/s41598-019-48388-7 10.1212/WNL.0000000000009107 10.1155/2012/384875 10.1001/jamaophthalmol.2020.0959 10.1007/s10792-018-0934-y 10.1007/s00401-018-01956-z 10.1002/mds.27914 10.1002/mds.20914 10.1002/acn3.767 |
ContentType | Journal Article |
Copyright | 2020 The Authors. published by Wiley Periodicals LLC on behalf of American Neurological Association. 2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. 2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2020 The Authors. published by Wiley Periodicals LLC on behalf of American Neurological Association. – notice: 2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. – notice: 2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK 7U7 C1K K9. 7X8 5PM |
DOI | 10.1002/ana.25944 |
DatabaseName | Open Access: Wiley-Blackwell Open Access Journals Wiley Online Library Journals Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Toxicology Abstracts Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: 24P name: Open Access: Wiley-Blackwell Open Access Journals url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Retinal Thinning and Cognition |
EISSN | 1531-8249 |
EndPage | 176 |
ExternalDocumentID | 10_1002_ana_25944 33098308 ANA25944 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Michael J. Fox Foundation for Parkinson's Research funderid: RRIA 2014 (Rapid Response Innovation Awards) Progr – fundername: Instituto de Salud Carlos III and co‐funded by European Union (ERDF/ESF, "A way to make Europe"/"Investing in your future") funderid: Juan Rodes grant JR15/00008; PI14/00679; PI16/00005 – fundername: Osasun Saila, Eusko Jaurlaritzako funderid: 2016111009; 2020333033 – fundername: ; grantid: 2016111009; 2020333033 – fundername: ; grantid: RRIA 2014 (Rapid Response Innovation Awards) Progr – fundername: Instituto de Salud Carlos III and co‐funded by European Union (ERDF/ESF, "A way to make Europe"/"Investing in your future") grantid: Juan Rodes grant JR15/00008; PI14/00679; PI16/00005 |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OB 1OC 1ZS 23M 24P 2QL 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEJM AAESR AAEVG AAHHS AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABIVO ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBMB ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRZS ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFAZI AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE AJJEV ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM EBS EJD EMOBN F00 F01 F04 F5P F8P FEDTE FUBAC FYBCS G-S G.N GNP GODZA GOZPB GRPMH H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M J5H JPC KBYEO KD1 KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LXL LXN LXY LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB O66 O9- OHT OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.- Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWD RWI RX1 SAMSI SJN SUPJJ TEORI UB1 V2E V8K V9Y VH1 W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 XJT XPP XSW XV2 YOC YQJ ZGI ZRF ZRR ZXP ZZTAW ~IA ~WT ~X8 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK 7U7 C1K K9. 7X8 5PM |
ID | FETCH-LOGICAL-c4434-720b3acb25a6bc9e427594217bbd9af5f6475f072e6cd04f127d79bffcbe03c23 |
IEDL.DBID | 24P |
ISSN | 0364-5134 |
IngestDate | Tue Sep 17 21:07:04 EDT 2024 Fri Aug 16 09:32:08 EDT 2024 Fri Aug 30 23:48:59 EDT 2024 Fri Aug 23 02:59:09 EDT 2024 Sat Sep 28 08:24:20 EDT 2024 Sat Aug 24 01:05:28 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Attribution-NonCommercial 2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4434-720b3acb25a6bc9e427594217bbd9af5f6475f072e6cd04f127d79bffcbe03c23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-3765-1005 0000-0002-7715-3764 0000-0001-6045-2840 0000-0002-9808-6943 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fana.25944 |
PMID | 33098308 |
PQID | 2470493527 |
PQPubID | 946345 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7756646 proquest_miscellaneous_2454113487 proquest_journals_2470493527 crossref_primary_10_1002_ana_25944 pubmed_primary_33098308 wiley_primary_10_1002_ana_25944_ANA25944 |
PublicationCentury | 2000 |
PublicationDate | January 2021 |
PublicationDateYYYYMMDD | 2021-01-01 |
PublicationDate_xml | – month: 01 year: 2021 text: January 2021 |
PublicationDecade | 2020 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Minneapolis |
PublicationTitle | Annals of neurology |
PublicationTitleAlternate | Ann Neurol |
PublicationYear | 2021 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2018; 141 1984; 41 2002; 59 2019; 9 2015; 5 2012; 2012 2019; 6 1984; 47 2020; 40 2019; 34 2019; 39 2020; 35 2000; 111 2020; 10 2013; 120 2020; 98 1998; 21 2014; 83 2011; 310 2016; 57 2014; 137 1990; 40 2010; 67 2004; 55 2015; 67 2018; 8 1987; 110 2019; 64 2017; 58 2006; 21 2020; 94 1991; 41 2003; 8 2007; 130 2019; 137 2020; 138 2018; 91 2005; 53 2016; 63 2016; 139 2008; 22 2020; 87 2012; 7 2018; 33 2018; 59 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 Ojeda N (e_1_2_8_31_1) 2016; 63 e_1_2_8_47_1 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_41_1 e_1_2_8_40_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 Lanskey JH (e_1_2_8_2_1) 2018; 141 Diederich NJ (e_1_2_8_10_1) 1998; 21 e_1_2_8_32_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
References_xml | – volume: 34 start-page: 1315 year: 2019 end-page: 1324 article-title: Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases publication-title: Mov Disord – volume: 59 start-page: 1249 year: 2002 end-page: 1252 article-title: Progressive worsening of spatial and chromatic processing deficits in Parkinson disease publication-title: Arch Neurol – volume: 35 start-page: 349 year: 2020 end-page: 354 article-title: Retina thickness as a marker of neurodegeneration in prodromal lewy body disease publication-title: Mov Disord – volume: 8 start-page: s992 year: 2003 end-page: s997 article-title: Visual‐spatial ability in Parkinson's disease publication-title: Front Biosci – volume: 5 start-page: 125 year: 2015 end-page: 130 article-title: Abnormal visual contrast acuity in Parkinson's disease publication-title: J Parkinson Dis – volume: 67 start-page: 48 year: 2015 article-title: Fitting linear mixed‐effects models using lme4 publication-title: J Stat Softw – volume: 91 start-page: e1003 year: 2018 end-page: e1012 article-title: Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease publication-title: Neurology – volume: 87 start-page: 533 year: 2020 end-page: 546 article-title: Visual dysfunction of the superior colliculus in de novo parkinsonian patients publication-title: Ann Neurol – volume: 22 start-page: 729 year: 2008 end-page: 737 article-title: Visuospatial deficits predict rate of cognitive decline in autopsy‐verified dementia with Lewy bodies publication-title: Neuropsychology – volume: 33 start-page: 1315 year: 2018 end-page: 1324 article-title: Phosphorylated α‐synuclein in the retina is a biomarker of Parkinson's disease pathology severity publication-title: Mov Disord – volume: 310 start-page: 86 year: 2011 end-page: 89 article-title: Initial neuropsychological impairments in patients with the E46K mutation of the alpha‐synuclein gene (PARK 1) publication-title: J Neurol Sci – volume: 130 start-page: 1787 year: 2007 end-page: 1798 article-title: Evolution of cognitive dysfunction in an incident Parkinson's disease cohort publication-title: Brain – volume: 111 start-page: 66 year: 2000 end-page: 74 article-title: Visual contrast response functions in Parkinson's disease: evidence from electroretinograms, visually evoked potentials and psychophysics publication-title: Clin Neurophysiol – volume: 47 start-page: 673 year: 1984 end-page: 678 article-title: Visual fatigue and visual evoked potentials in multiple sclerosis, glaucoma, ocular hypertension and Parkinson's disease publication-title: J Neurol Neurosurg Psychiatry – volume: 40 start-page: 1483 year: 2020 end-page: 1491 article-title: Characterization by fractal dimension analysis of the retinal capillary network in Parkinson disease publication-title: Retina – volume: 94 start-page: 481 year: 2020 end-page: 494 article-title: Disease modification and biomarker development in Parkinson disease: revision or reconstruction? publication-title: Neurology – volume: 58 start-page: 1151 year: 2017 end-page: 1157 article-title: Evaluation of progressive visual dysfunction and retinal degeneration in patients with Parkinson's disease publication-title: Investig Ophthalmol Vis Sci – volume: 41 start-page: 485 year: 1984 end-page: 490 article-title: Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors publication-title: Arch Neurol – volume: 67 start-page: 64 year: 2010 end-page: 70 article-title: The clinically important difference on the Unified Parkinson's Disease Rating Scale publication-title: Arch Neurol – volume: 137 start-page: 379 year: 2019 end-page: 395 article-title: Retinal alpha‐synuclein deposits in Parkinson's disease patients and animal models publication-title: Acta Neuropathol – volume: 8 start-page: 85 year: 2018 end-page: 92 article-title: Progressive changes in the retinal structure of patients with Parkinson's disease publication-title: J Parkinsons Dis – volume: 110 start-page: 1675 year: 1987 end-page: 1698 article-title: Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity publication-title: Brain – volume: 21 start-page: 289 year: 1998 end-page: 295 article-title: Poor visual discrimination and visual hallucinations in Parkinson's disease publication-title: Clin Neuropharmacol – volume: 64 start-page: 40 year: 2019 end-page: 49 article-title: Retinal layers in Parkinson's disease: a meta‐analysis of spectral‐domain optical coherence tomography studies publication-title: Parkinsonism Relat Disord – volume: 141 start-page: 2545 year: 2018 end-page: 2560 article-title: Can neuroimaging predict dementia in Parkinson's disease? publication-title: Brain – volume: 57 start-page: 5696 year: 2016 end-page: 5704 article-title: Visual contrast sensitivity in early‐stage Parkinson's disease publication-title: Investig Ophthalmol Vis Sci – volume: 98 start-page: e479 year: 2020 end-page: e486 article-title: Longitudinal changes in the thickness of the ganglion cell‐inner plexiform layer in patients with hypertension: a 4‐year prospective observational study publication-title: Acta Ophthalmol – volume: 83 start-page: 1253 year: 2014 end-page: 1260 article-title: Predictors of dementia in Parkinson disease: a prospective cohort study publication-title: Neurology – volume: 139 start-page: 2827 year: 2016 end-page: 2843 article-title: Visual dysfunction in Parkinson's disease publication-title: Brain – volume: 120 start-page: 2485 year: 2013 end-page: 2492 article-title: Impact of age‐related change of retinal nerve fiber layer and macular thicknesses on evaluation of glaucoma progression publication-title: Ophthalmology – volume: 34 start-page: 141 year: 2019 end-page: 152 article-title: Vision loss and 12‐year risk of dementia in older adults: the 3C cohort study publication-title: Eur J Epidemiol – volume: 6 start-page: 902 year: 2019 end-page: 912 article-title: Neural correlates of early cognitive dysfunction in Parkinson's disease publication-title: Ann Clin Transl Neurol – volume: 39 start-page: 1255 year: 2019 end-page: 1262 article-title: Functional and morphological assessment of ocular structures and follow‐up of patients with early‐stage Parkinson's disease publication-title: Int Ophthalmol – volume: 137 start-page: 849 year: 2014 end-page: 859 article-title: Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations publication-title: Brain – volume: 53 start-page: 695 year: 2005 end-page: 699 article-title: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment publication-title: J Am Geriatr Soc – volume: 63 start-page: 488 year: 2016 end-page: 496 article-title: Montreal Cognitive Assessment test: normalization and standardization for Spanish population publication-title: Rev Neurol – volume: 21 start-page: 1200 year: 2006 end-page: 1207 article-title: Minimal clinically important change on the Unified Parkinson's Disease Rating Scale publication-title: Mov Disord – volume: 40 start-page: 1710 year: 1990 end-page: 1714 article-title: Spatiotemporal contrast sensitivity differs in normal aging and Parkinson's disease publication-title: Neurology – volume: 7 year: 2012 article-title: The OSCAR‐IB consensus criteria for retinal OCT quality assessment publication-title: PLoS One – volume: 138 start-page: 624 year: 2020 end-page: 633 article-title: Association of visual impairment with risk of incident dementia in a Women's Health Initiative population publication-title: JAMA Ophthalmol – volume: 10 start-page: 29 year: 2020 end-page: 39 article-title: Visual tests predict dementia risk in Parkinson disease publication-title: Neurol Clin Pract – volume: 9 start-page: 11832 year: 2019 article-title: Inner retinal thinning as a biomarker for cognitive impairment in de novo Parkinson's disease publication-title: Sci Rep – volume: 59 start-page: 4115 year: 2018 end-page: 4122 article-title: Retinal microvascular impairment in the early stages of Parkinson's disease publication-title: Investig Ophthalmol Vis Sci – volume: 41 start-page: 1200 year: 1991 end-page: 1202 article-title: Spatial contrast sensitivity is reduced in bilateral Parkinson's disease publication-title: Neurology – volume: 2012 start-page: 384875 year: 2012 article-title: Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review publication-title: J Aging Res – volume: 55 start-page: 164 year: 2004 end-page: 173 article-title: The new mutation, E46K, of alpha‐synuclein causes Parkinson and Lewy body dementia publication-title: Ann Neurol – ident: e_1_2_8_38_1 doi: 10.1002/ana.25696 – ident: e_1_2_8_45_1 doi: 10.1002/mds.27392 – ident: e_1_2_8_21_1 doi: 10.1002/mds.27728 – ident: e_1_2_8_12_1 doi: 10.1212/WNL.41.8.1200 – ident: e_1_2_8_23_1 doi: 10.1016/j.parkreldis.2019.04.023 – ident: e_1_2_8_28_1 doi: 10.3233/JPD-171184 – ident: e_1_2_8_30_1 doi: 10.1111/j.1532-5415.2005.53221.x – ident: e_1_2_8_29_1 doi: 10.1371/journal.pone.0034823 – ident: e_1_2_8_9_1 doi: 10.2741/1171 – volume: 141 start-page: 2545 year: 2018 ident: e_1_2_8_2_1 article-title: Can neuroimaging predict dementia in Parkinson's disease? publication-title: Brain contributor: fullname: Lanskey JH – ident: e_1_2_8_43_1 doi: 10.1007/s10654-018-00478-y – ident: e_1_2_8_46_1 doi: 10.1097/IAE.0000000000002641 – ident: e_1_2_8_40_1 doi: 10.1093/brain/aww175 – ident: e_1_2_8_5_1 doi: 10.1037/a0012949 – volume: 63 start-page: 488 year: 2016 ident: e_1_2_8_31_1 article-title: Montreal Cognitive Assessment test: normalization and standardization for Spanish population publication-title: Rev Neurol contributor: fullname: Ojeda N – volume: 21 start-page: 289 year: 1998 ident: e_1_2_8_10_1 article-title: Poor visual discrimination and visual hallucinations in Parkinson's disease publication-title: Clin Neuropharmacol contributor: fullname: Diederich NJ – ident: e_1_2_8_14_1 doi: 10.3233/JPD-140470 – ident: e_1_2_8_7_1 doi: 10.1093/brain/110.6.1675 – ident: e_1_2_8_11_1 doi: 10.1001/archneur.59.8.1249 – ident: e_1_2_8_16_1 doi: 10.1167/iovs.16-20025 – ident: e_1_2_8_4_1 doi: 10.1002/ana.10795 – ident: e_1_2_8_35_1 doi: 10.1016/j.ophtha.2013.07.021 – ident: e_1_2_8_39_1 doi: 10.1093/brain/awt360 – ident: e_1_2_8_19_1 doi: 10.1212/CPJ.0000000000000719 – ident: e_1_2_8_17_1 doi: 10.1136/jnnp.47.7.673 – ident: e_1_2_8_13_1 doi: 10.1016/S1388-2457(99)00223-0 – ident: e_1_2_8_15_1 doi: 10.1212/WNL.40.11.1710 – ident: e_1_2_8_34_1 doi: 10.1001/archneurol.2009.295 – ident: e_1_2_8_44_1 doi: 10.1212/WNL.0000000000006157 – ident: e_1_2_8_6_1 doi: 10.1016/j.jns.2011.07.047 – ident: e_1_2_8_20_1 doi: 10.1212/WNL.0000000000000842 – ident: e_1_2_8_27_1 doi: 10.1167/iovs.16-20460 – ident: e_1_2_8_32_1 doi: 10.18637/jss.v067.i01 – ident: e_1_2_8_47_1 doi: 10.1167/iovs.17-23230 – ident: e_1_2_8_36_1 doi: 10.1111/aos.14291 – ident: e_1_2_8_8_1 doi: 10.1001/archneur.1984.04050170031011 – ident: e_1_2_8_18_1 doi: 10.1093/brain/awm111 – ident: e_1_2_8_24_1 doi: 10.1038/s41598-019-48388-7 – ident: e_1_2_8_3_1 doi: 10.1212/WNL.0000000000009107 – ident: e_1_2_8_41_1 doi: 10.1155/2012/384875 – ident: e_1_2_8_42_1 doi: 10.1001/jamaophthalmol.2020.0959 – ident: e_1_2_8_26_1 doi: 10.1007/s10792-018-0934-y – ident: e_1_2_8_22_1 doi: 10.1007/s00401-018-01956-z – ident: e_1_2_8_25_1 doi: 10.1002/mds.27914 – ident: e_1_2_8_33_1 doi: 10.1002/mds.20914 – ident: e_1_2_8_37_1 doi: 10.1002/acn3.767 |
SSID | ssj0009610 |
Score | 2.5711446 |
Snippet | Objective
This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in... This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic... ObjectiveThis study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in... OBJECTIVEThis study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 165 |
SubjectTerms | Adult Atrophy Biomarkers Cognitive ability Cognitive Dysfunction - complications Cognitive Dysfunction - genetics Confidence intervals Dementia disorders Evaluation Female Humans Lewy bodies Lewy Body Disease - genetics Male Middle Aged Movement disorders Mutation Nerve Fibers - metabolism Neurodegeneration Neurodegenerative diseases Optical Coherence Tomography Parkinson Disease - complications Parkinson Disease - congenital Parkinson Disease - genetics Parkinson's disease Reduction Retina Retinal Ganglion Cells - metabolism Risk Thickness Tomography Tomography, Optical Coherence - methods Visual Fields - genetics Visual Fields - physiology |
Title | Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fana.25944 https://www.ncbi.nlm.nih.gov/pubmed/33098308 https://www.proquest.com/docview/2470493527/abstract/ https://search.proquest.com/docview/2454113487 https://pubmed.ncbi.nlm.nih.gov/PMC7756646 |
Volume | 89 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1RS-QwEB72PJB7OfS8O6veEcWHe6mmyaTZck-Lq8jBiiwKvpWkTXARuuKu__8m6bbrIgf3UgqZ0mYmk3yTyXwFOPXSUmjscvI07lM0mU2NMj4tnPOB4atSMRUzucmv7_HPg3oYwO-uFqblh-g33IJnxPk6OLixi_M1aahpzBlhd8QP8JFgzTAMaYG3a8bdPFIRhDxbqjKJHa0QF-f9o5uL0TuE-f6g5FsAG1egqx34vIKObNTaehcGrvkC25NVcnwPJtNQvkwSd4-z6ilMYez2JbQuF4xgHpvOFk9s7tlFd2KIjV0ojHRs1rBQ_RwLwdi4Tdl8hfury7uL63T1t4S0QpSYasGtNJUVyuS2KhwKTV2kiMPaujBe-Ry18lwLl1c1R58JXevCel9Zx2Ul5DfYauaN2wcW0m3a1dRvXiNFXIUpuPeZsqgNd84mcNKprXxuSTHKlv5YlKTbMuo2gaNOoeXKLxalQE0hCYE-ncBx30wjOqQpTOPmr0FGYUYGG5LM91b__Vuk5MVQ8mECesMyvUBgy95saWaPkTVba0KumCfwK9rw3x9ejm5G8ebg_0UP4ZMIh13i3swRbC1fXt0PQitL-zOOSrqOp-Iv7fXmhg |
link.rule.ids | 230,315,786,790,891,1382,11589,27957,27958,46087,46329,46511,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NIQEvjK9B2ACDeOAlneOPuJF4qTamAmuFqk7aC4psx9aqSila2xf-es5Ok9FNkxBvkXxWHJ_P_p3v7heAj54bdI1djpZGfSp0ZlIttU8L53xg-LIyhmJG43x4Lr5dyIsd-NzWwjT8EN2FW7CMuF8HAw8X0kfXrKG61j0E70Lcg_to7jI6VJNr8qgij1wEIdCWyoyLlleIsqOu6_ZpdAti3s6U_BvBxiPodA9-toNvMk_mvfXK9OzvG7yO__t1T-DxBpuSQbOYnsKOq5_Bg9Em-v4cRpNQH40S08uZnYc9kvy4Cq2rJUEcSSaz5ZwsPDluU5LIiQuVl47MahLKq2OlGTlpYkIv4Pz0y_R4mG5-x5BaIbhIFaOGa2uY1LmxhRNM4fjQpTGmKrSXPhdKeqqYy21Fhc-YqlRhvLfGUW4Z34fdelG7V0BCPE-5CueVVgJdukIX1PtMGqE0dc4k8KFVS_mrYd0oG35lVuLElHFiEjhsFVZuDG9ZMqHQ50FUqRJ43zWjyYQ4iK7dYh1kpMhwQfRR5mWj3-4tnNOiz2k_AbWl-U4g0HFvt9Szy0jLrRRCY5En8Ckq9u6Bl4PxID68_nfRd_BwOB2dlWdfx98P4BELmTXxIugQdldXa_cGodHKvI0W8AcC3QnC |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Ra9swED66Fspextatm7du1cYe-uJVlk5WTJ9Cs9BuSwilhb4ZyZZoKDilSf__TnLsNpTB3gw6YetOJ32n030G-O6lpdDY5eRp3KdoMpsaZXxaOOcDw1elYipmMs3PrvDXtbregpOuFqblh-gP3IJnxPU6OPhd7Y8fSUNNY34Qdkd8ATuY80GIvATOHhl380hFEPJsqcokdrRCXBz3XTc3o2cI8_lFyacANu5A49fwag0d2bC19RvYcs0e7E7WyfG3MLkI5cskcXkzr27DEsZm96F1tWQE89jFfHnLFp6ddjeG2MiFwkjH5g0L1c-xEIyN2pTNO7ga_7w8PUvXf0tIK0SJqRbcSlNZoUxuq8Kh0DREijisrQvjlc9RK8-1cHlVc_SZ0LUurPeVdVxWQu7DdrNo3AdgId2mXU3j5jVSxFWYgnufKYvacOdsAt86tZV3LSlG2dIfi5J0W0bdJnDQKbRc-8WyFKgpJCHQpxP42jfTjA5pCtO4xUOQUZiRwQYk877Vf_8WKXkxkHyQgN6wTC8Q2LI3W5r5TWTN1pqQK-YJHEUb_vvDy-F0GB8-_r_oIezORuPyz_n09yd4KcK9l3hMcwDbq_sH95mAy8p-iRP0L5BK6DA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Retinal+Thickness+Predicts+the+Risk+of+Cognitive+Decline+in+Parkinson+Disease&rft.jtitle=Annals+of+neurology&rft.au=Murueta-Goyena%2C+Ane&rft.au=Del+Pino%2C+Roc%C3%ADo&rft.au=Gald%C3%B3s%2C+Marta&rft.au=Arana%2C+Bego%C3%B1a&rft.date=2021-01-01&rft.eissn=1531-8249&rft.volume=89&rft.issue=1&rft.spage=165&rft_id=info:doi/10.1002%2Fana.25944&rft_id=info%3Apmid%2F33098308&rft.externalDocID=33098308 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0364-5134&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0364-5134&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0364-5134&client=summon |